


# Blood test can predict optimal treatment for advanced prostate cancer, study finds

July 24 2018

---



Dr. Alison Allan, scientist at Lawson Health Research Institute. Credit: Lawson Health Research Institute

An international collaborative study between Lawson Health Research Institute, Memorial Sloan Kettering Cancer Center, the Royal Marsden

and Epic Sciences is one of the first to demonstrate that a blood test can predict how patients with advanced prostate cancer will respond to specific treatments, leading to improved survival.

The study used a liquid biopsy [test](#) developed by molecular diagnostics company Epic Sciences that examines circulating tumour cells (CTCs) in blood samples from patients with advanced [prostate cancer](#) who are deciding whether to switch from hormone-targeting therapy to chemotherapy. CTCs are cancer cells that leave a tumour, enter the blood stream and invade other parts of the body, causing the spread of cancer.

The test identifies whether or not a patient's CTCs contain a protein called AR-V7 in the cell's nucleus. The research team set out to determine whether the presence of this protein predicted which treatment would best prolong a patient's life. They found that patients who tested positive for the protein responded best to taxane-based chemotherapy while those who tested negative for the protein responded best to hormone-targeting therapy with drugs called androgen-receptor signaling (ARS) inhibitors. These are the two most widely used drug classes to treat advanced prostate cancer.

"The study focused on a critical decision point when patients and their oncologists are choosing what therapy to pursue next," says Dr. Alison Allan, a scientist at Lawson and Chair, Department of Anatomy & Cell Biology at Western University's Schulich School of Medicine & Dentistry. "We are addressing a critical unmet need by validating that a [blood test](#) or liquid biopsy can be used to select a therapy most likely to extend a patient's life."

Research participants included 142 patients with advanced prostate cancer from the London Regional Cancer Program at London Health Sciences Centre (LHSC) in London, Ontario; Memorial Sloan Kettering

Cancer Center in New York; and the Royal Marsden in London, England. The patients had already undergone at least one round of hormone-targeting therapy without success and were working with their oncologist to decide whether to switch to a different hormone-targeting therapy or to chemotherapy as their next line of treatment.

Hormone-targeting therapies like ARS inhibitors work by slowing or stopping the growth of cancers that use hormones to grow. Prostate cancer growth relies on hormones called androgens, which include testosterone. Androgen deprivation therapy like ARS inhibitors blocks the production of male hormones to treat the recurrence or spread of prostate cancer.

"ARS inhibitors are the preferred first line of treatment because they target the hormones that provide the fuel for [prostate cancer cells](#) to grow," explains Dr. Allan. "However, at some point, cancer cells can figure out a way to survive without this fuel and become resistant to ARS inhibitors, in many cases through production of the AR-V7 protein. That's why chemotherapy is sometimes used a second line therapy."

While this study looked at predicting the best treatment for patients who had already undergone at least one round of hormone-targeting therapy, a future goal of the team is to assess the use of this test or similar CTC blood tests in determining optimal [therapy](#) at earlier decision points in advanced [prostate cancer](#) care. The team also plans to collaborate further with Epic Sciences to evaluate different versions of the CTC blood test for other types of cancer, such as lung cancer.

Through Epic Sciences' partnership with Genomic Health, the CTC blood test is now commercially available in the United States as the Oncotype DX AR-V7 Nucleus Detect.

**More information:** Howard I. Scher et al, Assessment of the Validity

of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer, *JAMA Oncology* (2018). [DOI: 10.1001/jamaoncol.2018.1621](https://doi.org/10.1001/jamaoncol.2018.1621)

Provided by Lawson Health Research Institute

Citation: Blood test can predict optimal treatment for advanced prostate cancer, study finds (2018, July 24) retrieved 10 April 2024 from <https://medicalxpress.com/news/2018-07-blood-optimal-treatment-advanced-prostate.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--